Welcome to our dedicated page for ARTIVION SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
A holder of AORT common stock filed a notice of intent to sell 616 shares, with an aggregate market value of $17,586.18, through Fidelity Brokerage Services LLC on August 14, 2026 on the NYSE. These shares relate to restricted stock vesting as compensation on August 12, 2026, and follow a prior sale of 44,001 shares for $910,753.51 on June 11, 2026 by Andrew M. Green.
Artivion, Inc. received an amended ownership report showing that Nomura Asset Management International Inc. and Nomura Investment Management Business Trust together beneficially own 3,184,974 shares of Artivion common stock. This represents 6.5% of the common stock outstanding as of June 30, 2026.
The filing states that the firms have shared voting and dispositive power over 3,184,974 shares and no sole voting or dispositive power. The ownership percentage is calculated using 48,692,000 shares outstanding, derived from 50,179,000 shares issued minus 1,487,000 treasury shares, as reported in Artivion’s Form 10-Q for the quarter ended June 30, 2026.
Jean F. Holloway, SVP and General Counsel of Artivion, Inc., reported a sale of 977 shares of Artivion common stock on 2026-08-12 in a transaction categorized as a "Sale in open market or private transaction" at a price of $28.49 per share. Following this sale, Holloway directly holds 184,118 shares of Artivion common stock. The filing’s Rule 10b5-1 checkbox is unchecked, and a footnote states that the reported price reflects the price at which the shares were sold.
Artivion, Inc. reported stronger top-line results but weaker profitability for the quarter ended June 30, 2026. Total revenues grew 11% year over year to $125,757 thousand, and six‑month revenues rose 14% to $242,094 thousand, driven mainly by aortic stent grafts and On‑X mechanical heart valves. Aortic stent graft revenues increased 16% in the quarter and 19% year to date, while On‑X products rose 19% and 20%, respectively.
Despite higher gross margin dollars, Artivion posted an operating loss of $8,364 thousand versus prior‑year operating income of $8,384 thousand, and a quarterly net loss of $13,510 thousand compared with net income of $1,345 thousand. Results were pressured by higher general, administrative, and marketing expenses, increased research and development spending, acquisition‑related costs of $12,500 thousand tied to the Endospan transaction, and a $9,710 thousand increase in fair value of contingent consideration related to Ascyrus. Interest expense remained elevated at $7,253 thousand for the quarter.
Artivion closed the Endospan acquisition with total consideration fair value of $178,062 thousand, adding $99,206 thousand of goodwill and $71,800 thousand of identifiable intangibles, and recognized new contingent consideration of $26,227 thousand. Separately, FDA Premarket Approval of the AMDS Hybrid Prosthesis in June 2026 triggered a $25,000 thousand milestone payment and raised AMDS‑related contingent liabilities to $70,290 thousand. To fund growth, total principal debt increased to $370,000 thousand, including a full draw of the $150,000 thousand delayed‑draw term loan, while cash and cash equivalents rose to $77,316 thousand. Operating cash flow was near breakeven for the first half. The company also disclosed an ongoing German tax examination with potential additional exposure of about €7 million if the tax authority’s position prevails, but recorded no adjustment based on its current ASC 740 assessment.
Artivion, Inc. reported second quarter 2026 revenue of $125.8 million, up 11% on a GAAP basis and 9% on a non-GAAP constant currency basis versus the second quarter of 2025. The company posted a GAAP net loss of $13.5 million, or $(0.28) per diluted share, while non-GAAP net income was $6.3 million, or $0.13 per diluted share. Adjusted EBITDA increased 7% to $26.4 million.
Artivion completed the acquisition of Endospan Ltd., adding the NEXUS Aortic Arch Stent Graft System, and received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis, expanding its aortic arch portfolio. For full-year 2026, Artivion reiterated revenue guidance of $480 to $496 million and adjusted EBITDA guidance of $92 to $99 million.
FMR LLC and Abigail P. Johnson report beneficial ownership of Artivion Inc common stock. As of 06/30/2026, FMR LLC reports 1,963,471.40 shares beneficially owned, representing 4.0% of the class, with sole dispositive power over the same amount and no shared voting or dispositive power. Abigail P. Johnson is reported as having sole dispositive power over the same 1,963,471.40 shares, also representing 4.0% of the common stock. The filing indicates ownership of 5 percent or less of the class, with one or more other persons entitled to dividends or sale proceeds, but no such person has more than five percent of the outstanding common stock.
ARTIVION, INC. senior vice president Andrew M. Green reported an exercise-and-sell transaction in company stock. He exercised stock options for a total of 44,001 shares of common stock at exercise prices of $11.03 and $18.44 per share, then sold the same 44,001 shares in open-market transactions at weighted average prices of $20.694 and $20.707 per share. These trades were carried out on June 11, 2026 under a pre-arranged Rule 10b5-1 trading plan. Following the transactions, Green continued to hold 60,259 shares of Artivion common stock directly.
Artivion, Inc. senior vice president of Regulatory and Quality, Andrew M. Green, filed an initial ownership report. He holds 60,259 shares of common stock directly, including 41,529 restricted stock units that each represent a contingent right to receive one share. He also holds stock options for 30,000 shares at an exercise price of $11.03 expiring in 2029 and options for 14,001 shares at $18.44 expiring in 2029.